Please assess the completion status of the following clinical trial:

Trial Title: EXtended Therapy in Hepatitis C Genotype 3 Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infected with only genotype 3, hepatitis C~* Treatment naïve before current course of therapy~* A positive HCV RNA test result at Week 4 (no RVR)~* A negative HCV RNA test result at Week 12 (cEVR)~* A recent liver biopsy (within 3 years prior to study entry) is required. If the patient has either liver biopsy proven cirrhosis in the past or has splenomegaly with features of cirrhosis on ultrasound and/or thrombocytopenia (\<150x109/ml) at any time in the past or has a Fibroscan reading of 10 or above or has a Fibrotest score of 0.75 or above (equivalent to F3 on the METAVIR scale), a biopsy will not be required. A copy of the latest report must be available.~Exclusion Criteria:~* Under age 18~* Co-infection with HIV or Hepatitis B or any other HCV genotype in addition to genotype 3~* Prior treatment for Hepatitis C aside from herbal remedies~* Evidence of decompensated liver disease, such as ascites, bleeding varices, hepatic encephalopathy or jaundice (conjugated hyperbilirubinemia)~* INR \> 1.3 at baseline~* Platelet count \<70 X 109/μl at baseline~* Those subjects with diabetes and/or systemic hypertension will need to have ocular examinations (as per standard of care \[SOC\]) prior to treatment and will be excluded if they are found to have a diabetic retinopathy, optic nerve disorders, retinal hemorrhage or any other clinically significant abnormality~* Pre-existing psychiatric conditions including:~  * Current moderate or severe depression despite appropriate therapy.~ * Active suicidal ideation or previous attempt at suicide~ * Patients with a history of severe psychiatric disorder (may be included if so desired by the investigator but pretreatment psychiatric evaluation is required (SOC)).~ * Clinical diagnosis of current substance abuse: Alcohol (\>40g/d), injection drugs, inhalational drugs (not including marijuana), psychotropics, narcotics, cocaine use, prescription or over the counter drugs within one year of the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care treatment (Type: NO_INTERVENTION): Participants will be randomized to receive only the standard 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin).
- Extended therapy (Type: ACTIVE_COMPARATOR): Participants will be randomized to receive 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin) in addition to their standard of care therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).